Tivic Shareholders Approve Key Proposals for Biopharmaceutical Expansion; Lisa Wolf Appointed Permanent CFO

Tivic Health Systems shareholders have approved key proposals for the company's strategic transformation, including the issuance of equity for Entolimod and Entolasta, targeting acute radiation syndrome and neutropenia. The company is expanding its biopharmaceutical focus, with Lisa Wolf appointed as permanent CFO. CEO Jennifer Ernst emphasized the successful establishment of a strong foundation for Tivic's expansion into the biopharmaceutical sector.

Tivic Health Systems, Inc. (NASDAQ: TIVC), a micro-cap biotech company, has seen its stock rise after shareholders approved key proposals at its annual meeting on June 30, 2025. The proposals, which are crucial for the company's strategic transformation, include the issuance of equity for Entolimod and Entolasta, targeting acute radiation syndrome and neutropenia. These therapies are being developed for uses in acute radiation syndrome, neutropenia, and other oncology and hematology indications [1].

The company also received shareholder approval for equity issuance related to previously announced financing arrangements, both of which required approval under Nasdaq listing rules. According to Tivic Health's CEO, Jennifer Ernst, the successful approval of these proposals establishes a strong foundation for the company's expansion into biopharmaceutical markets [1].

In addition to the strategic proposals, Tivic Health announced leadership changes. Lisa Wolf has been appointed as the permanent Chief Financial Officer after serving as interim CFO for nine months. Blake Gurfein, who has been the Chief Scientific Officer for eight years, will step down from his role but will continue to support the company’s Vagus Nerve Stimulation program as a consultant [1].

Tivic Health, which describes itself as a diversified immunotherapeutics company, has previously commercialized ClearUP, an FDA-approved product. The company is now expanding its portfolio with the newly licensed therapies, Entolimod and Entolasta. Despite facing operational challenges and a significant revenue decline of -54.5% over the last twelve months, the company maintains a healthy current ratio of 1.7 and a market capitalization of just $3.5 million [1].

The stock of Tivic Health Systems, Inc. rose 5% after the shareholder approval, indicating investor confidence in the company's strategic direction and the potential of its new therapies [2]. The company is optimistic about future developments, with plans to file a Biological Licensing Application and achieve key milestones later in the year.

References:
[1] https://www.investing.com/news/company-news/tivic-health-shareholders-approve-strategic-transformation-proposals-93CH-4126572
[2] https://www.investing.com/news/stock-market-news/tivic-health-stock-rises-after-shareholders-approve-strategic-proposals-93CH-4126570